Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL) (original) (raw)

Gene Therapy volume 5, pages 1622–1630 (1998)Cite this article

Abstract

Fas ligand is a type II transmembrane protein which can induce apoptosis in Fas-expressing cells. Recent reports indicate that expression of FasL in transplanted cells may cause graft rejection and, on the other hand, tumor cells may lose their tumorigenicity when they are engineered to express FasL. These effects could be related to recruitment of neutrophils by FasL with activation of their cytotoxic machinery. In this study we investigated the antitumor effect of allogenic fibroblasts engineered to express FasL. Fibroblasts engineered to express FasL (PA317/FasL) did not exert toxic effects on transformed liver cell line (BNL) or colon cancer cell line (CT26) in vitro, but they could abrogate their tumorigenicity in vivo. Histological examination of the site of implantation of BNL cells mixed with PA317/FasL revealed massive infiltration of polymorphonuclear neutrophils and mononuclear cells. A specific immune protective effect was observed in animals primed with a mixture of BNL or CT26 and PA317/FasL cells. Rechallenge with tumor cells 14 or 100 days after priming resulted in protection of 100 or 50% of animals, respectively. This protective effect was due to CD8+ cells since depletion of CD8+ led to tumor formation. In addition, treatment of pre-established BNL tumors with a subcutaneous injection of BNL and PA317/FasL cell mixture at a distant site caused significant inhibition of tumor growth. These data demonstrate that allogenic cells engineered with FasL are able to abolish tumor growth and induce specific protective immunity when they are mixed with neoplastic cells.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Division of Hepatology and Gene Therapy, Department of Medicine, School of Medicine and Clinica Universitaria, University of Navarra, Pamplona, 31080, Spain
    M Drozdzik, C Qian, JJ Lasarte, R Bilbao & J Prieto

Authors

  1. M Drozdzik
    You can also search for this author inPubMed Google Scholar
  2. C Qian
    You can also search for this author inPubMed Google Scholar
  3. JJ Lasarte
    You can also search for this author inPubMed Google Scholar
  4. R Bilbao
    You can also search for this author inPubMed Google Scholar
  5. J Prieto
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Drozdzik, M., Qian, C., Lasarte, J. et al. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).Gene Ther 5, 1622–1630 (1998). https://doi.org/10.1038/sj.gt.3300763

Download citation

Keywords

This article is cited by